Dr Jessie Mole
The Dr Jessie Mole lecture was inaugurated on 10 December 2001, in recognition of Jessie's outstanding contribution to BRPS, then RP Fighting Blindness and now Retina UK.
Resources
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.